Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature by Angus Nnamdi Oli, Samson Adedeji Adejumo, Adekunle Babajide Rowaiye, Joyce Oloaigbe Ogidigo, Jarrad Hampton-Marcell, Gordon C. Ibeanu

“…We also explore the latest advancements in combination therapies, which synergistically integrate multiple immunotherapeutic strategies to overcome resistance and enhance therapeutic outcomes. …”
Get full text

Development and Validation of an Immunotherapy-Related Prognostic Signature Based on Lymph Node Ratio for Gastric Cancer by Jianxin Li, Ting Han, Xin Wang, Yinchun Wang, Xuan Chen, Wangsheng Chen, Qingqiang Yang

“…We then evaluated the risk score signature from the viewpoints of survival, clinic-pathological characteristics, tumor microenvironment (TME), tumor mutation burden (TMB), and immunotherapeutic and chemotherapeutic efficacy. Results. …”
Get full text

Exosome-Associated Gene Signature for Predicting the Prognosis of Ovarian Cancer Patients by Zihan Zhu, Rui Geng, Yixin Zhang, Jinhui Liu, Jianling Bai

“…We also assessed the function of the ERGRS to forecast immunotherapeutic efficacy by immunophenoscore (IPS). Results. …”
Get full text

NEIL3 Mediates Lung Cancer Progression and Modulates PI3K/AKT/mTOR Signaling: A Potential Therapeutic Target by Hongbo Huang, Qingwang Hua

“…The predicted result of TIDE indicated that immunotherapeutic nonresponders had elevated NEIL3 levels. …”
Get full text

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients by Kamel Ait-Tahar, Amanda P. Anderson, Martin Barnardo, Graham P. Collins, Chris S. R. Hatton, Alison H. Banham, Karen Pulford

“…This is the first report of a CTL and a CD4 Th response to Sp17 in DLBCL and supports Sp17 as a potential immunotherapeutic target for DLBCL.…”
Get full text

A Severe Case of Ipilimumab-Induced Ileocolitis Refractory to Glucocorticosteroids and Infliximab by Behdod Poushanchi, Hiren Vallabh, Gorman Joel Reynolds

“…Ipilimumab is a monoclonal antibody that works as an immunotherapeutic agent through selective targeting of T cells to strengthen the response to metastatic melanoma. …”
Get full text

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment by Liubov A. Tashireva, Irina V. Larionova, Irina V. Larionova, Nikita A. Ermak, Anastasia A. Maltseva, Ekaterina I. Livanos, Anna Yu. Kalinchuk, Marina N. Stakheyeva, Larisa A. Kolomiets

“…The identification of predictive biomarkers for immunotherapeutic response and the innovative agents capable of reversing resistance pathways must be developed. …”
Get full text

Investigation of Scutellaria Barbata’s immunological mechanism against thyroid cancer using network pharmacology and experimental validation by Gen Ouyang, Yuangui Zhu, Zhehao Ouyang

“…The expression, prognosis, and immunotherapeutic roles of core genes were validated using TCGA databases. …”
Get full text

Reprogramming the tumor immune microenvironment using engineered dual-drug loaded Salmonella by Dinh-Huy Nguyen, Sung-Hwan You, Hien Thi-Thu Ngo, Khuynh Van Nguyen, Khang Vuong Tran, Tan-Huy Chu, So-young Kim, Sang-Jun Ha, Yeongjin Hong, Jung-Joon Min

“…Abstract Synergistic combinations of immunotherapeutic agents can improve the performance of anti-cancer therapies but may lead to immune-mediated adverse effects. …”
Get full text

Comprehensive single-cell pan-cancer atlas unveils IFI30+ macrophages as key modulators of intra-tumoral immune dynamics by Lihe Jiang, Lihe Jiang, Lihe Jiang, Peili Wang, Peili Wang, Yixuan Hou, Jingying Chen, Hua Li, Hua Li

“…IFI30 emerges as a prospective intervention point in the immunotherapeutic landscape.…”
Get full text

Clinical Diagnosis of an Autoimmune Encephalitis Presented as a Manic Episode with Psychotic Symptoms: A Case Report by Miguel Soto Ontoso, Ruben A. Piernas González, Isabel Ramírez Martínez, José Miguel Meca García

“…In places where there is no antibody measurement, or when its measurement is negative, the clinical suspicion supported by CSF studies, magnetic resonance imaging, and electroencephalographic recording, should guide us to start immunotherapeutic treatment early. The early initiation of treatment ensures the reversibility of the neurological disorder in the vast majority of patients.…”
Get full text

Heterogeneity of cancer-associated fibroblast subpopulations in prostate cancer: Implications for prognosis and immunotherapy by Chen Ding, Jiange Wang, Jie Wang, Jiqiang Niu, Zhikai Xiahou, Zhou Sun, Zhenzhen Zhao, Dongyang Zeng

“…Conclusion: This investigation illuminates the critical potential of targeting CAFs to augment immunotherapeutic approaches in prostate cancer. Our findings contribute to a deeper understanding of the TME's complexity, advocating for further exploration into CAF-targeted therapies aimed at enhancing treatment responses and ultimately improving patient outcomes.…”
Get full text

A reasonable Approach for the Treatment of HIV Infection in the Early Phase with Ozonetherapy (Autohaemotherapy). How ‘Inflammatory’ Cytokines may have A therapeutic Role by V. Bocci

“…In the last 7 years we have clarified the main mechanisms of action of an unorthodox immunotherapeutic method first used 40 years ago. Optimized autohaemotherapy after a brief exposure ofblood to ozone may today afford the trick of reprogramming the immune system to keep HIV at bay. …”
Get full text

Lessons from Cancer Immunoediting in Cutaneous Melanoma by Mariana Aris, María Marcela Barrio, José Mordoh

“…We will describe the different immunotherapeutic strategies employed and consider current models accounting for tumor heterogeneity. …”
Get full text

Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles by Kowichi Jimbow, Yasue Ishii-Osai, Shosuke Ito, Yasuaki Tamura, Akira Ito, Akihiro Yoneta, Takafumi Kamiya, Toshiharu Yamashita, Hiroyuki Honda, Kazumasa Wakamatsu, Katsutoshi Murase, Satoshi Nohara, Eiichi Nakayama, Takeo Hasegawa, Itsuo Yamamoto, Takeshi Kobayashi

“…Magnetite nanoparticles were conjugated with NPrCAP to introduce thermotherapeutic and immunotherapeutic effects through nonapoptotic cell death and generation of heat shock protein (HSP) upon exposure to alternating magnetic field (AMF). …”
Get full text

Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer by Marketa Skalickova, Marketa Skalickova, Katerina Hadrava Vanova, Ondrej Uher, Jindriska Leischner Fialova, Jindriska Leischner Fialova, Jindriska Leischner Fialova, Katerina Petrlakova, Michal Masarik, Michal Masarik, Michal Masarik, Michal Masarik, Zdeněk Kejík, Zdeněk Kejík, Pavel Martasek, Karel Pacak, Milan Jakubek, Milan Jakubek

“…In the context of locally advanced or metastatic cancer, combining diverse immunotherapeutic and other treatment strategies targeting multiple cancer hallmarks appears crucial. …”
Get full text

A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy by Jin Bian, Yan Niu, Yanli Ma, Fuhua Chen, Ning Ma

“…Herein, we have extensively addressed the role of the PD-1/PD-L1 axis in the immunotherapy of EBV-associated NPC. Immunotherapeutic strategies are anticipated to enter mainstream clinical practise and provide long-term remissions in patients with severe NPC.…”
Get full text

Advancements in targeted and immunotherapy strategies for glioma: toward precision treatment by Guangyuan Gong, Lang Jiang, Jing Zhou, Yuanchao Su

“…This review explores the current status and recent advancements in targeted and immunotherapeutic approaches for high-grade gliomas.…”
Get full text

Invariant NKT Cells as Novel Targets for Immunotherapy in Solid Tumors by Karsten A. Pilones, Joseph Aryankalayil, Sandra Demaria

“…Increased understanding of the signals that determine the function of NKT cells in cancer will be essential to improve current strategies for NKT-cell-based immunotherapeutic approaches.…”
Get full text

Glutamate Receptors in Neuroinflammatory Demyelinating Disease

“…The preclinical development of compounds for MS has generally followed a conventional, immunotherapeutic route. However, over the past decade, a group of compounds that suppress EAE but have no apparent immunomodulatory activity have emerged. …”
Get full text